Gilmore O’Neill
Chief Executive Officer at EDITAS MEDICINE, INC.
Net worth: 2 M $ as of 2024-03-30
Profile
Gilmore O’Neill occupies the position of Chief Medical Officer & Executive Vice President at Sarepta Therapeutics, Inc. Dr. O’Neill is also on the board of Massachusetts Biotechnology Council and Unity Biotechnology, Inc. and Member of American Academy of Neurology. In his past career he held the position of Senior Vice President for Biogen, Inc. Gilmore O’Neill received an undergraduate degree from University College Dublin and a graduate degree from Harvard University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
EDITAS MEDICINE, INC.
0.40% | 2024-03-04 | 327,470 ( 0.40% ) | 2 M $ | 2024-03-30 |
| 2023-06-22 | 0 ( -.--% ) | - $ | 2024-03-30 |
Gilmore O’Neill active positions
| Companies | Position | Start |
|---|---|---|
| UNITY BIOTECHNOLOGY, INC. | Director/Board Member | 2020-12-13 |
| EDITAS MEDICINE, INC. | Chief Executive Officer | 2022-05-31 |
American Academy of Neurology
 American Academy of Neurology Miscellaneous Commercial ServicesCommercial Services American Academy of Neurology operates a professional society which represents neurologists and neuroscientists. The company was founded in 1948 and is headquartered in Minneapolis, MN. | Corporate Officer/Principal | - |
Massachusetts Biotechnology Council
 Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell. | Director/Board Member | - |
Former positions of Gilmore O’Neill
| Companies | Position | End |
|---|---|---|
| APTINYX | Director/Board Member | 2023-04-13 |
| SAREPTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-11-16 |
| BIOGEN INC. | Chief Tech/Sci/R&D Officer | 2018-05-31 |
Training of Gilmore O’Neill
| Harvard University | Graduate Degree |
| University College Dublin | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| BIOGEN INC. | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| EDITAS MEDICINE, INC. | Health Technology |
| APTINYX | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Massachusetts Biotechnology Council
Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell. | Commercial Services |
American Academy of Neurology
American Academy of Neurology Miscellaneous Commercial ServicesCommercial Services American Academy of Neurology operates a professional society which represents neurologists and neuroscientists. The company was founded in 1948 and is headquartered in Minneapolis, MN. | Commercial Services |
- Stock Market
- Insiders
- Gilmore O’Neill
